Nymox Pharmaceutical Corporation (NYMX) |
|
0.2863 -0.01 (-3.34%)
|
12-02 15:59 |
|
Open: |
0.2961 |
Pre. Close: |
0.2962 |
|
High:
|
0.2962 |
Low:
|
0.28 |
|
Volume:
|
167,540 |
Market Cap:
|
26(M) |
|
|
|
Technical analysis |
as of: 2022-12-02 4:25:01 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.39  One year: 0.44 |
| Support: |
Support1: 0.28 Support2: 0.23 |
| Resistance: |
Resistance1: 0.34 Resistance2: 0.37 |
| Pivot: |
0.31 |
| Moving Average: |
MA(5): 0.3 MA(20): 0.31
MA(100): 0.37 MA(250): 0.84 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 6.8 %D(3): 10 |
| RSI: |
RSI(14): 34.1 |
| 52-week: |
High: 2.09 Low: 0.18 |
| Average Vol(K): |
3-Month: 71 (K) 10-Days: 52 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NYMX ] has closed below the lower bollinger band by 4.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 63.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 27 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.3 - 0.3 |
0.3 - 0.3 |
|
Low:
|
0.27 - 0.28 |
0.28 - 0.28 |
|
Close:
|
0.28 - 0.29 |
0.29 - 0.29 |
|
Company Description |
|
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas. |
Headline News |
Fri, 25 Nov 2022
May 2023 Market Cap Requirement Update - Nymox Pharmaceutical (NASDAQ:NYMX) - Benzinga
Sun, 09 Oct 2022
Insiders might want to re-evaluate their US$1.9m stock purchase as Nymox Pharmaceutical Corporation (NASDAQ:NYMX) drops to US$32m - Simply Wall St
Tue, 13 Sep 2022
NYMOX Provides Current Update - GlobeNewswire
Wed, 17 Aug 2022
Is Nymox Pharmaceutical (NASDAQ:NYMX) In A Good Position To Deliver On Growth Plans? - Simply Wall St
Fri, 15 Jul 2022
NYMOX Updates Shareholders - GlobeNewswire
Wed, 25 May 2022
Nymox tanks as FDA rejects NDA for fexapotide - The Pharma Letter
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
91 (M) |
| Shares Float |
51 (M) |
|
% Held by Insiders
|
45 (%) |
|
% Held by Institutions
|
0.8 (%) |
|
Shares Short
|
1,820 (K) |
|
Shares Short P.Month
|
1,760 (K) |
Stock Financials |
|
EPS
|
-0.19 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
-0.21 |
|
EPS Est Next Year
|
-0.57 |
|
Book Value (p.s.)
|
0.01 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-145.2 |
|
Return on Equity (ttm)
|
-284.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.15 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-8 (M) |
|
Levered Free Cash Flow
|
-6 (M) |
Stock Valuations |
|
PE Ratio
|
-1.57 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
14.31 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-3.31 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
